Everand Logo

Welcome to Everand!

  • STAT

    LISTEN: The AI hype machine, ketamine’s future, and the rocky path ahead for NASH

    When will #AI replace your radiologist? What can #pharma learn from ketamine? And is liver disease more complicated than anyone thought? Find out on this week's episode of our #biotech…
    by Damian Garde and Rebecca Robbins and Adam Feuerstein Feb 14, 2019 1 minute

    When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

    We discuss all that and

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
    Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
    Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
    Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

    Related Books & Audiobooks